MOB3B Antibody

What is MOB3B and why is it important for cancer research?

MOB3B (Monopolar spindle-binding protein 3B) functions as a signal transducer and is involved in crucial cellular processes including cell division, growth, and cell cycle progression . It shares similarity with the yeast Mob1 protein, which binds Mps1p, a protein kinase essential for spindle pole body duplication and mitotic checkpoint regulation .

Recent research has identified MOB3B as a potential tumor suppressor, particularly in colorectal cancer (CRC), where loss of MOB3B expression is associated with poor prognosis . Its role in regulating mTOR/autophagy signaling makes it a significant target for investigating diseases characterized by abnormal cell growth .

What applications are MOB3B antibodies validated for in research settings?

MOB3B antibodies have been validated for multiple experimental applications:

Researchers should conduct optimization experiments to determine the optimal dilution for their specific experimental conditions and sample types .

What is the recommended protocol for MOB3B antibody use in immunohistochemistry?

For immunohistochemical detection of MOB3B in tissue specimens:

• Tissue preparation: Fix tissues in formalin and embed in paraffin. Prepare 4-μm-thick sections .

• Antigen retrieval: Deparaffinize and rehydrate sections, then perform antigen retrieval by boiling in a pressure cooker with EDTA-antigen retrieval solution (pH 8.0) for 10 minutes .

• Blocking steps:

  • Block endogenous peroxidase activity with 3% hydrogen peroxide for 30 minutes at room temperature

  • Block non-specific binding with normal goat serum for 30 minutes

• Primary antibody incubation: Incubate sections with polyclonal anti-MOB3B antibody at a dilution of 1:100-1:400 at 4°C overnight .

• Detection system: Incubate with biotin-labeled goat anti-rabbit IgG polymer, horseradish peroxidase-labeled streptomycin-working solution, and 3,3'-diaminobenzidine chromogenic solution in succession .

• Counterstaining: Counterstain with hematoxylin, dehydrate with a gradient alcohol series, and seal with neutral resin and coverslip .

This protocol has been validated for detecting MOB3B in colorectal cancer tissues and can be adapted for other tissue types .

How should MOB3B antibodies be stored and handled for optimal performance?

For maximum antibody stability and performance:

• Store at -20°C for long-term storage (up to one year)

• For frequent use, store at 4°C for up to one month to avoid freeze-thaw cycles

• When thawing, centrifuge the original vial prior to removing the cap to maximize recovery

• Consider aliquoting the antibody to avoid repeated freeze-thaw cycles

• Most MOB3B antibodies are provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

Proper storage and handling protocols significantly impact antibody performance and experimental reproducibility .

How does MOB3B regulate mTOR/autophagy signaling in cancer cells?

MOB3B functions as a tumor suppressor by modulating the mTOR/autophagy pathway . Research findings demonstrate:

• Molecular mechanism: MOB3B overexpression decreases phosphorylated mTOR (p-mTOR) levels, while knockdown enhances p-mTOR expression in CRC cells .

• Autophagy regulation:

  • MOB3B overexpression significantly induces LC3-II/I conversion and decreases SQSTM1/p62 expression

  • Transmission electron microscopy confirms increased autophagic flux in MOB3B-overexpressing cells

• Cell migration regulation:

  • MOB3B overexpression decreases matrix metalloproteinase (MMP2, MMP9) expression

  • This decrease correlates with reduced cell migration and invasion capacities

• Experimental validation: Treatment with mTOR agonist (MHY1485) in MOB3B-overexpressing cells restores p-mTOR levels and inhibits autophagy, while mTOR inhibitor (rapamycin) in MOB3B-knockdown cells activates autophagy and suppresses migration

These findings establish MOB3B as a negative regulator of mTOR signaling, promoting autophagy and inhibiting cancer cell migration through MMP suppression .

What methodological considerations should be addressed when assessing MOB3B expression in different experimental contexts?

Researchers should consider several methodological aspects when studying MOB3B:

• Antibody specificity:

  • Verify specificity through peptide blocking experiments

  • Confirm appropriate molecular weight detection (~25 kDa predicted, though 72 kDa has been observed in some systems)

  • Consider using multiple antibodies targeting different epitopes

• Expression detection optimizations:

  • For Western blot: Test multiple protein extraction methods, as MOB3B detection may be influenced by extraction protocols

  • For IHC: Evaluate different antigen retrieval methods; high-pressure and temperature Tris-EDTA (pH 8.0) has shown good results

• Experimental controls:

  • Include both positive controls (tissues/cells known to express MOB3B)

  • Include negative controls (antibody pre-absorbed with immunogen peptide)

  • When possible, include MOB3B knockdown or overexpression controls

• Quantification approaches:

  • For IHC: Use semi-quantitative scoring systems incorporating both staining intensity and percentage of positive cells

  • For Western blot: Normalize to appropriate loading controls and use multiple biological replicates

How can researchers establish stable MOB3B knockdown or overexpression models for functional studies?

Based on published methodologies, the following approaches are recommended:

• Lentiviral systems for stable modification:

  • For overexpression: Lentivirus carrying MOB3B cDNA (e.g., LV-MOB3B)

  • For knockdown: Lentivirus carrying MOB3B siRNA (e.g., LV-MOB3B-RNAi)

• Protocol for establishing stable cell lines:

  • Infect target cells at multiplicity of infection of 10

  • Select in media containing puromycin for approximately 7 days

  • Pick individual cell colonies and expand in new culture plates

  • Re-select in puromycin-containing media

  • Verify modification through Western blot and/or RT-PCR

• Validation considerations:

  • Confirm alteration at both mRNA and protein levels

  • Assess functional consequences (proliferation, migration, etc.)

  • For in vivo studies, conduct pre-validation of cells prior to xenograft experiments

• Experimental design considerations:

  • Include appropriate vector-only or non-targeting siRNA controls

  • Monitor for potential off-target effects

  • Consider the use of multiple siRNA sequences or CRISPR/Cas9 approaches for confirmation

What are the key considerations for using MOB3B antibodies in tumor tissue microarray (TMA) analyses?

When analyzing MOB3B expression across multiple tumor samples using TMAs:

• Sample preparation:

  • Ensure consistent fixation protocols across all samples

  • Consider the use of paired normal and tumor tissues from the same patients

• Antibody validation for TMA analysis:

  • Optimize antibody dilution specifically for TMA sections

  • Test on whole tissue sections before proceeding to TMA analysis

  • Include positive and negative control tissues on each TMA slide

• Scoring and quantification:

  • Implement a standardized scoring system for MOB3B expression

  • In published studies, MOB3B immunoreactivity was scored semi-quantitatively using the formula: Score = staining intensity × percentage of positive cells

  • Consider automated image analysis methods for more objective quantification

• Clinical correlation analyses:

  • Correlate MOB3B expression with clinical parameters (TNM stage, survival)

  • In CRC studies, loss of MOB3B expression correlated with poor prognosis (statistical significance p < 0.05)

  • Perform multivariate analyses to determine independent prognostic value

How do MOB3B expression patterns differ between normal tissues and cancer tissues?

Research findings demonstrate significant differences in MOB3B expression between normal and cancerous tissues:

• Expression in colorectal tissues:

  • MOB3B expression is significantly reduced in CRC compared to normal tissues

  • Loss of MOB3B expression correlates with poor clinical outcomes

• Subcellular localization:

  • In normal tissues, MOB3B shows primarily cytoplasmic localization

  • Altered subcellular distribution may be observed in certain cancer types

• Quantitative differences:

  • Immunohistochemical studies show variable staining intensity across different tumor grades

  • Western blot analyses confirm reduced protein levels in tumor tissues

• Tissue specificity considerations:

  • Expression patterns may vary across different cancer types

  • Researchers should validate antibodies for specific tissue types being studied

  • Human Protein Atlas data can serve as reference for expected tissue expression patterns

What methods can be used to investigate MOB3B interactions with other proteins in cellular signaling pathways?

To study MOB3B protein interactions and signaling:

• Co-immunoprecipitation (Co-IP):

  • Use anti-MOB3B antibodies to pull down protein complexes

  • Recommended dilution: 1:100-1:200 for immunoprecipitation

  • Western blot for potential interaction partners (e.g., components of mTOR pathway)

• Proximity ligation assay (PLA):

  • Enables visualization of protein interactions in situ

  • Requires antibodies from different host species for target proteins

  • Can detect transient or weak interactions in fixed cells or tissues

• Functional validation of interactions:

  • Investigate effects of MOB3B knockdown/overexpression on potential partners

  • In CRC studies, MOB3B expression affected levels of:

    • mTOR pathway components (p-mTOR)

    • Autophagy markers (LC3-II/I, SQSTM1/p62)

    • Matrix metalloproteinases (MMP2, MMP9)

• Mass spectrometry-based approaches:

  • Immunoprecipitate MOB3B and identify binding partners through LC-MS/MS

  • Consider SILAC or TMT labeling for quantitative interaction studies

  • Validate key interactions through orthogonal methods (Co-IP, PLA)